REG - Adv Medical Solutns. - US LiquiBand® distribution agreements signed

Advanced Medical SolutionsAnnouncement

25/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231025:nRSY1585Ra&default-theme=true

RNS Number : 1585R  Advanced Medical Solutions Grp PLC  25 October 2023

25 October 2023

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

All new US LiquiBand(®) hospital distribution agreements signed

 

New US route-to-market strategy now operational and expected to accelerate the
growth of LiquiBand(®) in the US from Q4 2023

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, today announces that
its new US LiquiBand(®) route-to-market strategy is fully operational
following the successful signing of all three hospital distribution
agreements.

The structure of each of these five-year agreements has been designed to
accelerate market share gains and build on the underlying momentum already
established by AMS and its partners in this growing $270 million market. This
new strategy will enable more product and brand differentiation that will be
further strengthened following the expected approval of the Connexicon range
in 2024.

Furthermore, the new route-to-market strategy has established a stronger
marketing platform to enable the recently launched LiquiBand(®) XL to gain
traction in the US market through all three distribution channels and to build
on the success that the product has already achieved, further accelerating
overall LiquiBand(®) growth.

The company can confirm that each of our partners have now completed the
transition to the new agreements and throughout the transition, end-user sales
have not been affected and there has been no impact on customers. In addition,
normal order patterns have resumed for all three partners.

Chris Meredith, Chief Executive Officer of AMS, commented: "The successful
signing of all three US distribution agreements is a significant step forward
for the Group and marks an important inflection  point for the growth of the
LiquiBand(®) portfolio. We are extremely proud of what we have achieved to
date in the US, having secured over 20 per cent of the available market. This
strengthened route-to-market strategy now provides greater opportunities for
us and is an important step in our ambition to more than double market share
in the medium term. I look forward to building even stronger and more
productive relationships with all our partners as we embark on this next phase
of the LiquiBand growth story."

 

- End -

 

 

For further information, please contact:

 

 Advanced Medical Solutions Group plc            Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Consilium                                   Tel: +44 (0) 20 3709 5700
 Matthew Neal / Lucy Featherstone

 Investec Bank PLC (NOMAD & Broker)              Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 HSBC Bank PLC (Broker)                          Tel: +44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

 

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®), LIQUIFIX™ and Seal-G(®). AMS also supplies wound care
dressings such as silver alginates, alginates and foams through its
ActivHeal(®) brand as well as under white label. Since 2019, the Group has
made five acquisitions: Sealantis, an Israeli developer of innovative internal
sealants; Biomatlante, a French developer and manufacturer of surgical
biomaterials, Raleigh, a leading UK coater and converter of woundcare and
bio-diagnostics materials, AFS Medical, an Austrian specialist surgical
business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group
has R&D innovation hubs in the UK, Ireland, Germany, France and Israel.
Established in 1991, the Group has more than 800 employees. For more
information, please see www.admedsol.com (http://www.admedsol.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRFLFIRIDLSFIV